Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

By T. Lang, K. Klein, J. Fischer, A. Nussler, P. Neuhaus, U. Hofmann, M. Eichelbaum, M. Schwab, Ulrich M. Zanger. Pharmacogenetics (London), 2001

623 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Pharmacology

View Paper: https://www.semanticscholar.org/paper/de9087cc6fbd6339d490b8898f2ceef6cec1fff3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. Shufeng Zhou
2. G. Wilkinson

In Pharmacology

1. Shufeng Zhou
2. M. Schwab
3. Jun-Ping Liu
4. B. Chowbay
5. G. Wilkinson
6. Ulrich M. Zanger

Citations in the corpus

• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The CYP2B6 gene is extensively polymorphic with numerous variants in the coding and noncoding regions of the gene (Lang et al., 2001; Lamba et al., 2003; Lang et al., 2004; Klein et al., 2005; Zukunft et al., 2005; Zanger et al., 2007).”
• Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study (2004, background): “At least ten CYP2B6 single nucleotide polymorphisms have been identified, of which six result in altered amino acid sequence [16,17].”
• Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “However, in vitro studies in human liver samples found that mutated protein with R487C had decreased activity for S-mephenytoin N-demethylation (Lang et al., 2001).”
• Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction (2006, background): “Although historically human CYP2B6 was thought to play only a minor role in drug metabolism, more recent estimates suggest that CYP2B6 is involved in the metabolism of nearly 25% of drugs on the market today [82], such as the anticancer drugs cyclophosphamide and tamoxifen [83], the anaesthetics ket”
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity (2003, background): “, 2003), protein (Code et al., 1997; Stresser and Kupfer, 1999; Faucette et al., 2000; Lang et al., 2001), and catalytic activity (Ekins et al.”